Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Samir Moussa, PhD

Principal Scientist
Entasis Therapeutics

Disclosure(s): Entasis Therapeutics: Employee, Stocks/Bonds

Poster(s):

518 - Characterization of colistin-resistant (COL-R) Acinetobacter baumannii calcoaceticus complex (ABC) isolates from a recent, global Phase 3 trial (ATTACK)
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET